Summer Body, Summer Ready: How to Work Backwards from Your Holiday to Get Your Mounjaro or Wegovy Start Date Right

Every year, as spring arrives and summer holidays creep onto the calendar, a familiar question surfaces: is there still time to start a weight loss injection programme before July? It is a completely understandable thought — and the good news is that, with the right planning, the answer is often yes.

The challenge is that Mounjaro (tirzepatide) and Wegovy (semaglutide), the two leading weight loss injections licensed in the UK, are not quick fixes. They are clinically effective, evidence-based treatments — but they work progressively, over months rather than weeks. Understanding the timeline honestly is the key to setting expectations that are both motivating and realistic.

At Happy Pharmacy, a GPhC-registered online pharmacy, our personal approach to weight loss support means guiding patients through exactly these questions. This guide walks you through how to work backwards from your summer holiday date to choose the right start time — and what results you can realistically expect along the way.

Why Timing Matters With Weight Loss Injections

Unlike a crash diet, weight loss injections work by gradually recalibrating the hormonal signals that regulate hunger, fullness, and blood sugar. Both Mounjaro and Wegovy follow a structured dose titration schedule, starting at a low dose and increasing every four weeks to minimise side effects and allow the body to adjust.

This means there is an unavoidable biological lead-in period. The first four weeks are primarily about adjustment: your body is getting used to the medication, appetite signals are beginning to shift, but visible weight loss on the scale may be modest. The more significant results come later, typically from weeks eight to sixteen onwards, when the dose has escalated and the medication's full mechanism is in effect.

Clinical trial data from the SURMOUNT-1 study, published in the New England Journal of Medicine, showed that participants on Mounjaro's highest dose (15mg) lost an average of 22.5% of their body weight over 72 weeks — but the vast majority of that loss occurred between weeks twelve and thirty-six, not in the first month.¹

This is not a reason to delay — it is a reason to plan.

Average weight loss figures from SURMOUNT-1 (tirzepatide) and STEP-1 / STEP UP (semaglutide) clinical trials. Real-world figures typically 5–8% over 12 months (refs 1–3). Individual results vary.

The Week-by-Week Timeline: What to Realistically Expect

The table below summarises the typical weight loss trajectory for both Mounjaro and Wegovy based on clinical trial data, along with a practical description of what patients experience at each stage.

Sources: SURMOUNT-1 (tirzepatide, NEJM 2022), STEP UP trial (semaglutide 7.2mg, MHRA-approved January 2026), STEP-1 (semaglutide 2.4mg). Individual results vary. Figures represent approximate ranges from published data.

An important caveat: real-world outcomes tend to be more modest than trial figures. A 2024 systematic review and meta-analysis of 53 studies involving over 21,000 patients found that real-world weight reduction on GLP-1 receptor agonists typically sits in the range of two to eight per cent after one year — significantly below the headline trial figures, largely due to adherence, dose-holding, and the absence of the structured support programmes that characterise clinical trials.

This is precisely why the quality of the pharmacy and prescribing service you choose matters enormously — and why regulated, personal support from a trusted provider like Happy Pharmacy is such a meaningful part of the equation.

Working Backwards from Your Holiday: A Practical Countdown

The single most useful thing you can do right now is pick a date — your holiday departure, your beach event, your wedding — and count back from it. Here is a practical planning framework based on current evidence and UK clinical timelines.

Planning guide based on standard Mounjaro/Wegovy titration schedules and clinical trial data. Timings are approximate. Individual results vary — consult your prescriber for personalised guidance.

What NICE and NHS Guidance Says About Realistic Expectations

Both NICE Technology Appraisal TA875 (for semaglutide/Wegovy) and TA1026 (for tirzepatide/Mounjaro) make clear that these medications are intended as part of a holistic weight management programme — not standalone solutions. The guidance requires that treatment is provided alongside a reduced-calorie diet, increased physical activity, and ongoing clinical support.

This is not bureaucratic box-ticking. The data consistently shows that patients who engage with structured lifestyle support alongside their medication achieve meaningfully better and more sustained results. A 2025 retrospective study published in JMIR Formative Research, examining patients in a remote weight management programme, found that twelve-month outcomes were considerably improved among those who maintained regular clinical contact and lifestyle coaching.

NHS England's rollout of Mounjaro through primary care, which began in June 2025 under TA1026, specifically mandates wraparound behavioural and dietary support for at least nine months from the point of prescribing. In the private and online pharmacy setting, the same principle holds — regulated providers like Happy Pharmacy structure their programmes to mirror this standard of care.

Managing Expectations: What a 'Summer Result' Actually Looks Like

It is worth being direct about this: if you are starting in April 2026 with a July holiday in mind, you are unlikely to achieve the dramatic headline results seen in 72-week clinical trials. That is simply not enough time.

What is achievable, for many patients, is a meaningful and visible shift. Research from the British Heart Foundation, citing a University of Oxford meta-analysis published in 2026, found that people lost an average of 14.7kg after around nine months on newer weight loss medications. At twelve to sixteen weeks — a realistic pre-summer window — you might realistically expect five to ten per cent body weight reduction, noticeable changes in clothing fit, a significant reduction in appetite and food cravings, and measurably improved energy and wellbeing.

These outcomes are genuinely meaningful. And critically, the longer you continue on a well-managed programme, the more they compound. The patients who start in April do not just see summer results — they are building the foundation for lasting change.

The Safety Element

Both Mounjaro and Wegovy are MHRA-approved treatments with established safety profiles. That said, they are prescription-only medications for a reason. Common side effects — particularly gastrointestinal symptoms such as nausea and constipation — are most likely during dose escalation and typically resolve as the body adjusts.

It is essential to start your programme through a regulated provider. Counterfeit and unlicensed versions of these medications continue to circulate online, and their safety and efficacy cannot be verified. Happy Pharmacy dispenses only MHRA-approved, licensed medication, following a clinical review with a UK-registered prescriber — as required by GPhC guidelines.

The Bottom Line: Start Now, Plan Honestly, Trust the Process

If summer is your motivating deadline, April and early May is a genuinely strategic time to begin. You have enough weeks ahead of you to move through the adjustment and dose escalation phases and begin experiencing meaningful results before your holiday arrives.

The key is approaching it with honesty about the timeline, commitment to the lifestyle elements that make the medication work better, and the ongoing personal support of a regulated, trusted provider.

Weight loss injections are not a shortcut — they are a clinical tool. Used correctly, with the right support, they can deliver results that feel life-changing. And for many patients, summer is simply the beginning.

Start your journey with us today and take our online weight loss consultation — regulated, personal, and here for you.

Blog medically reviewed by : Palvinder Deol, GPhC Registered Pharmacist, 27 April 2026

References

1. New England Journal of Medicine. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216.

2. New England Journal of Medicine. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002.

3. MHRA. Wegovy 7.2mg approval based on STEP UP trial data. Second Nature GLP-1 week-by-week timeline).

4. NICE Technology Appraisal TA875. Semaglutide for managing overweight and obesity.  nice.org.uk/guidance/ta875

5. British Heart Foundation, citing University of Oxford 2026 BMJ meta-analysis . bhf.org.uk — Weight-loss injections explained.

Happy Pharmacy  |  HappyPharmacy.co.uk  |  GPhC-Registered Online Pharmacy

This blog is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any new treatment.